Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/10/2025

Vancomycin-Resistant E. faecium Treatment Guidelines

Primary Treatment Recommendations

  • The Infectious Diseases Society of America recommends linezolid 600 mg IV or PO every 12 hours as the preferred first-line treatment for VRE faecium bacteremia and serious infections 1
  • The European Society of Clinical Microbiology and Infectious Diseases suggests high-dose daptomycin (8-12 mg/kg/day, preferably ≥9 mg/kg) as the alternative first-line bactericidal option for serious VRE infections 2, 3, 1
  • The World Health Organization recommends tigecycline specifically for intra-abdominal infections involving VRE (100 mg IV loading dose, then 50 mg IV q12h), but advises against its use for bacteremia due to low serum levels 4, 5, 6, 7, 1

Site-Specific Treatment Algorithm

  • For VRE bacteremia or serious infections, the American College of Physicians recommends linezolid 600 mg IV/PO q12h as the first choice 1
  • For VRE bacteremia or serious infections, the International Society for Antimicrobial Chemotherapy suggests daptomycin 8-12 mg/kg IV daily as an alternative 2, 3, 1
  • For intra-abdominal VRE infections, the Surgical Infection Society recommends tigecycline (polymicrobial) or linezolid (monomicrobial) 4, 5

Critical Pitfalls to Avoid

  • The Centers for Disease Control and Prevention advise against using tigecycline for VRE bacteremia due to inadequate serum concentrations despite in vitro activity 2, 6, 7, 1
  • The Society for Healthcare Epidemiology of America emphasizes the importance of differentiating colonization from infection before initiating any anti-VRE therapy 2, 3, 7, 1
  • The Infectious Diseases Society of America recommends removing central venous catheters and other infection sources when treating VRE bacteremia 3, 1
  • The European Society of Clinical Microbiology and Infectious Diseases advises against relying on doxycycline monotherapy for serious VRE infections when linezolid or daptomycin are available 4, 5, 1